Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NYSE MKT | Common Stock
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.
Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG.
The company is headquartered in Hackensack.
New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | 0.22 Increased by +540.00% | -0.01 Increased by +2.30 K% |
| Mar 12, 26 | -0.07 Decreased by -177.78% | 0.04 Decreased by -300.00% |
| Nov 13, 25 | 0.03 Increased by 0.00% | 0.06 Decreased by -50.00% |
| Aug 14, 25 | -0.04 Decreased by -33.33% | 0.03 Decreased by -233.33% |
| May 9, 25 | -0.05 Increased by +16.67% | 0.08 Decreased by -162.50% |
| Mar 12, 25 | 0.09 Increased by +228.57% | 0.07 Increased by +28.57% |
| Nov 14, 24 | 0.03 Increased by +200.00% | 0.06 Decreased by -50.00% |
| Aug 14, 24 | -0.03 Decreased by -114.29% | 0.02 Decreased by -250.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 33.75 M Increased by +233.73% | 18.32 M Increased by +606.13% | Increased by +54.27% Increased by +251.66% |
| Dec 31, 25 | 9.12 M Decreased by -49.93% | -5.50 M Decreased by -184.76% | Decreased by -60.34% Decreased by -269.27% |
| Sep 30, 25 | 17.85 M Decreased by -0.60% | 2.35 M Decreased by -27.22% | Increased by +13.19% Decreased by -26.78% |
| Jun 30, 25 | 15.66 M Increased by +16.21% | 164.00 K Increased by +107.44% | Increased by +1.05% Increased by +106.41% |
| Mar 31, 25 | 10.11 M Increased by +169.82% | -3.62 M Increased by +21.24% | Decreased by -35.79% Increased by +70.81% |
| Dec 31, 24 | 18.22 M Increased by +73.74% | 6.49 M Increased by +207.45% | Increased by +35.65% Increased by +161.84% |
| Sep 30, 24 | 17.96 M Increased by +73.60% | 3.24 M Increased by +274.73% | Increased by +18.02% Increased by +200.65% |
| Jun 30, 24 | 13.47 M Decreased by -61.59% | -2.20 M Decreased by -111.39% | Decreased by -16.35% Decreased by -129.65% |